Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $266.98M.
ENTERPRISE VALUE (EV)
$266.98M
Treace Medical Concepts, Inc.
Market Cap
$263.71M
Enterprise Value (EV)
$266.98M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| Treace Medical Concepts, Inc. (TMCI) | $263.71M | $266.98M |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $263.97M | $232.77M |
| Scribe Therapeutics Inc. (SCTX)vs › | $262.31M | N/A |
| TriSalus Life Sciences, Inc. (TLSI)vs › | $266.00M | $254.14M |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $262.00M | $173.91M |
| Palisade Bio, Inc. (PALI)vs › | $261.24M | $136.07M |
| OraSure Technologies, Inc. (OSUR)vs › | $260.94M | $112.45M |
| Fate Therapeutics, Inc. (FATE)vs › | $267.50M | $310.75M |
| SAB Biotherapeutics, Inc. (SABS)vs › | $268.41M | $265.27M |
| Vanda Pharmaceuticals Inc. (VNDA)vs › | $269.11M | $236.06M |
Market Cap
$263.71M
Total Debt
$13.98M
Cash
$10.71M
Enterprise Value
$266.98M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
